Monday, February 21, 2011 4:25:29 PM
Section 30.2.5 in Chapter 5 of the CMS Part D manual addresses what they call "beneficiary protections". One of these protections is a mandate that formularies don't materially restrict access to drugs in the "Six Classes of Clinical Concern" aka "Protected Classes".
Antidepressants is one of the classes. The net result of the reg is that Part D sponsors must include virtually all drugs within the six classes on their formularies with minimal barriers (ie strict Prior Authorization). Thus, Viibyrd will be on all Part D formularies by this rule. CMS also has generous low income subsidies for many beneficiaries so even if plans put Viibyrd on a high cost tier many beneficiaries would still be able to access the drug at a low out of pocket expense.
http://www.cms.gov/PrescriptionDrugCovContra/Downloads/Chapter6.pdf
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM